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indirect comparison techniques. METHODS: All twelve-week randomised con-
trolled trials of olanzapine, quetiapine and aripiprazole conducted in monotherapy
or in adjunct therapy were identified through a literature review. Five mono-
therapy studies were found, allowing the comparison of asenapine versus quetia-
pine and aripiprazole, with olanzapine and haloperidol as common references,
using Bucher’s method (Bucher et al., J Clin Epidemiol 1997). One twelve-week and
four six-week placebo-controlled adjunctive therapy trials were identified, en-
abling the comparison of asenapine to olanzapine, quetiapine and aripiprazole
through pairwise comparisons using placebo as a common reference. The out-
comes used for comparison were the Young Mania Rating Scale (YMRS) change
from baseline, YMRS response and remission rates. RESULTS: In monotherapy,
the differences of mean YMRS change from baseline to week 12 between
asenapine versus quetiapine and aripiprazole were 0.10 (p0.959) and 1.76
(p0.342), respectively. Relative risks for response and remission were close to
one. In adjunct therapy, the differences of mean YMRS change from baseline to
week 6 between asenapine versus olanzapine, quetiapine and aripiprazole were
0.63 (p0.656), 0.10 (p0.967) and -0.10 (p0.946), respectively. Relative risks for
response and remission were numerically in favour of asenapine but not statis-
tically significant. CONCLUSIONS: The results of these indirect comparisons con-
sistently showed comparable efficacy of asenapine versus the investigated atypical
antipsychotics.
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OBJECTIVES: Reducing hospital readmission rates has emerged as an important
strategy for increasing the quality of health care, while reducing the cost of care. An
analysis was conducted using an US government-funded tool to investigate the
impact of post-hospitalization follow-up on readmissions for depression.
METHODS: Public (Medicare) and proprietary (MarketScan Commercial, Medicare
Supplemental and Medicaid) administrative databases were standardized and
linked via a common data model. A web-based tool was developed that captured
the logic typically required by CER methods, e.g. searches on drugs, diagnoses, and
procedures, application of time constraints, and development of variables for in-
tervention, outcomes and covariates. Patients with a hospitalization for depression
and was discharged to home were selected. Additional inclusion criteria were a
minimum of one year of enrollment prior to and 60 days of enrollment following
discharge. Patient claims histories were searched to determine outpatient visits
with 7 and 30 days post-discharge and rehospitalization within 30 days post-dis-
charge. SAS procedures embedded in the tool were utilized for bivariate and mul-
tivariate analyses. RESULTS: The study included 39,985 patients. Patients with a
follow-up visit were slightly older and were more likely to be female. Prior to index
hospitalization, patients with follow-up were more likely to have filled an antide-
pressant or antianxiety medication and had a diagnosis of depression or anxiety
pre-index hospitalization. Little difference was found in the rate of pre-period
hospitalization. A logistic regression model found that having a follow-up visit
within 7 days of discharge was negatively and statistically significantly associated
with having a readmission within 30 days (odds ratio  0.88, CI0.80 – 0.97, once
other factors (demographics, diagnosis, and drug treatment) were controlled.
CONCLUSIONS: The data model and tool may be leveraged in a similar manner to
compare drug and medical treatment options more rapidly and efficiently.
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OBJECTIVES: Few studies of mental illness in Africa have centered on Alzheimer’s
disease. The primary aim of the study was to determine the prescribing patterns
and cost of drugs for Alzheimer’s disease in a South African private health care
sector patient population. METHODS: A retrospective drug utilization study was
conducted. Data were obtained from a South African private medical aid adminis-
trator for 2010. The database consisted of 2,126,264 records for medication and
procedures.RESULTS:A total of only 25 patients (13 females and 12 males) received
114 medicine items for Alzheimer’s disease at a cost of R70 794.11 (average cost per
item R621.00 (SDR208.73)). This medicine is relatively expensive, yet not all med-
ical aid schemes pay for medication for Alzheimer’s disease. The average age of
patients was 72.52 (SD10.03) years, with ages ranging from 46 to 88 years. Me-
mantine was the most frequently prescribed active ingredient (42.98% of prescrib-
ing frequency and 46.35% of cost), followed by donepezil (40.35% of frequency and
41.59% of cost). The average cost per memantine prescription was R669.61, fol-
lowed by R640.12 for donepezil and R449.35 for galantamine. The different medical
aids only paid, on average, 78.86% of the total amount claimed by patients for these
medicines. Most products were claimed between February and June 2010. Average
Prescribed Daily Doses (PDDs) of active ingredients were generally lower than their
respective Defined Daily Doses (DDDs). The average PDD for memantine was 18.27
mg (DDD20 mg), for donepezil was 7.07 mg (DDD7.5 mg) and for galantamine
was only 6.95 mg (DDD16 mg). Most prescriptions for memantine (75.51%) were
prescribed in its PDD of 20 mg. CONCLUSIONS: The results were generally similar
to those of previous South African studies. Studies on larger patient populations
are necessary to investigate the cost-effectiveness of the different treatment
options.
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OBJECTIVES: In short term clinical trials antipsychotic medications are well toler-
ated by children under six years old. While concerns have been raised about the
impact of long term exposure on metabolic and cardiovascular health and on the
developing brain, little is known about the extent of long term antipsychotic expo-
sure in this age group. This study quantifies antipsychotic exposure over a 4 year
period of children who began antipsychotic treatment before their sixth birthday
and identifies the variables associated with the risk of long term exposure.
METHODS: Children were identified who initiated an index episode of antipsy-
chotic treatment before their sixth birthday in Florida’s fee for service Medicaid
program. Using claims data the medication utilization of these children was
tracked during the year before and the four years following the start of their index
episodes (pre-index and four post-index periods). Generalized estimating equa-
tions were used to identify variables associated with the risk of additional days of
antipsychotic exposure. RESULTS: Five hundred twenty-eight children were in-
cluded in the cohort. The mean total days of exposure was 821.9 (431.9) repre-
senting 56.3 % of all days during the four post-index periods. The mean days of
exposure to combinations of antipsychotics and other classes of psychotherapeu-
tic medications were 623.8 447.6 days. Children with primary diagnoses of per-
vasive developmental disorders and affective disorders were at greater risk of ad-
ditional days of exposure than children with ADHD. Exposure tended to be greater
among children with indicators of clinical complexity including the presence of
secondary diagnoses and the use of other classes of psychotherapeutic medica-
tions in addition to antipsychotics. CONCLUSIONS: Exposure to antipsychotic me-
diations was extensive. Although these children may have had complex and severe
problems, additional research is urgently needed on the benefits and risks of long
term antipsychotic exposure among very young children.
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OBJECTIVES: Up to one-third of older adults fall each year with medications rep-
resenting a well-known risk factor for falling. Ultimately, falls that result in injury
are the true target of fall prevention and are of interest to healthcare practitioners.
Therefore, this meta-analysis focused on evaluating the association of antipsy-
chotic and antidepressant drugs with hip fracture, a common and debilitating
fall-related injury. METHODS: A search of Pubmed/Medline was conducted from
1966-2010 with key words including “antipsychotic agents”, “psychotropic drugs”,
“antidepressive agents”, “aged”, and “hip fracture”. Inclusion criteria included
mean age 65 years and statistical adjustment or stratification by age and gender.
Excluded were studies where hip fractures were not distinguished from other frac-
ture types or authors failed to answer queries for required information. A random
effects model was used to calculate summary odds ratios for the specific classes of
psychotropic medications. RESULTS: Of 166 studies identified, 10 antipsychotic-
related studies and 14 antidepressant-related studies met the inclusion criteria.
Combined, these studies represent over 70,000 hip fracture cases and approxi-
mately 272,000 total subjects from eight different nations and four continents.
Summary odds ratios include (95% confidence interval): conventional antipsychot-
ics 1.68 (1.43, 1.99), atypical antipsychotics 1.30 (1.14, 1.49), tricyclic anti-depres-
sants 1.71 (1.43, 2.04), and selective serotonin re-uptake inhibitors 1.94 (1.37, 2.76).
Although some studies reported drug-specific risk measures, the availability of
drug-specific data was limited. CONCLUSIONS: All classes considered in this anal-
ysis are associated with an increased risk of hip fracture in older adults. There is a
trend towards reduced risk associated with atypical antipsychotics compared to
conventional antipsychotics, although this does not reach statistical significance.
To minimize the risk of hip fracture in older adults requiring psychotropic medi-
cations, further research examining the association of hip fractures to specific
drugs within these classes is essential.
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OBJECTIVES: This post-hoc analysis assessed the risk and the factors associated
with relapse and hospitalizations during the 2-year treatment of outpatients
treated with oral olanzapine or olanzapine long-acting injection (LAI). METHODS:
We used data of a 104-week multicenter, effectiveness study comparing oral and
LAI olanzapine in the treatment of outpatients with schizophrenia (n524;
NCT00320489). Relapse was defined as hospitalization for schizophrenia; a 25%
increase from baseline on the PANSS total score (if baseline score 40), a 10 point
increase (if baseline score 40); a 1-point increase from baseline on the CGI-S
scale, provided that final CGI-S score was 4; deliberate self-injury or injury to
others that is associated with worsening of psychosis; or discontinuation from the
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study because of worsening of psychosis. Functional activity was measured using
the resource utilization inventory. Non-adherent patients are those with non-ad-
herence as reason for discontinuation of the antipsychotic medication used at
baseline, per physician rating. RESULTS: Over the 2-year study, 30% of patients
have relapsed and 8% were hospitalized, without significant differences between
the two medication formulations. Patients non-adherent before baseline were
more likely to be hospitalized (14%) compared to adherent patients (7% hospital-
ized, p0.05). Relapse in non-adherent patients was 36% compared to 29% in ad-
herent patients. A logistic regression model on baseline factors associated with
relapse found that a greater extent of functional activity was associated with a
lower risk of relapse. The risk of subsequent hospitalization was significantly as-
sociated only with previous hospitalization. CONCLUSIONS: In this 2-year open
label study, the rate of relapse and hospitalization was similarly low among pa-
tients treated with oral olanzapine or olanzapine-LAI. While prior non-adherence
with oral antipsychotics and previous hospitalization were associated with hospi-
talization, only the latter predicted subsequent hospitalization in the logistic
model. Lower risk of relapse was associated with a greater level of productivity.
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OBJECTIVES: Treatment optimization for patients with schizophrenia remains a
challenge, and it is often difficult to determine whether augmenting the current
medication or switching to another will better benefit a patient. This post hoc
analysis compares outcome measures between patients whose antipsychotic med-
ication was either augmented or switched. METHODS: Adult outpatients receiving
oral antipsychotic treatment for schizophrenia were assessed during a 12-month,
multi-country, observational study (F1D-AY-B033). Clinical and functional out-
comes were assessed at the time of first treatment switch/augmentation (0–14
days preceding change) and compared between patients undergoing medication
augmentation or switching. Due to low numbers of patients with such data, inter-
pretation of findings is based on effect size (ES). RESULTS: Data at the time of
medication change were available for 87 patients (34 augmented, 53 switched). The
primary reason for treatment change in both groups was inadequate response, but
lack of adherence was more prevalent in the switched group (26.4% versus 8.8%).
Although changes in clinical severity from study initiation to medication change
were similar (per the Clinical Global Impressions—Severity scale), patients’ phys-
ical well being, as measured by physical component scores of the 12-item Short
Form Health Survey (SF-12), improved in the augmented group but worsened in the
switched group (augmented: 7.7111.98, switched: –1.8710.98, ES0.85). Simi-
larly, mental health state improved in the augmented group but declined in the
switched group, as indicated by SF-12 mental health component scores (augment-
ed: 2.4113.64, switched: –1.089.98, ES0.314). CONCLUSIONS: Patient’s wors-
ening or lack of meaningful improvement may prompt clinicians to switch anti-
psychotic medications, whereas, when a patient shows improvement, clinicians
appear more likely to try to bolster the improvement through augmentation with
another antipsychotic medication. Current findings are consistent with physicians’
stated reasons for augmenting versus switching antipsychotics in the treatment of
schizophrenia. Confirmation of these findings requires further research.
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OBJECTIVES: The risk of bradycardia and its consequences from use of cholinest-
erase inhibitors (ChI) in dementia was reported in epidemiological studies in 2009
and from a case series for memantine in 2008. We compared the detection and
timing of these associations between disproportionality analysis and published
epidemiological studies. METHODS: We conducted 1) a systematic review of the
literature to identify epidemiological studies reporting AEs in patients taking cur-
rently prescribed ChI and memantine, and 2) an analysis in the FDA spontaneous
Adverse Event Reporting System database (AERS) using the Empirical Bayesian
Geometric Mean (EBGM) statistic and 90% credibility intervals (90%CI), to allow for
low frequencies of drug-event pairs. A composite event consisted of any of the
following: bradycardia, bradyarrythmia, pacemaker insertion, complete atrio-ven-
tricular block and hip and femoral fracture. AEs from all drugs in AERS was the
comparator. RESULTS: A total of 246 cases suspected of being associated with ChI
and the composite event were identified. A statistically strong signal of dispropor-
tionate reporting, adjusted for age, sex and year was observed (EBGM of 6.58, 90%CI:
5.79 – 7.47). Cumulative yearly analyses revealed that the signal became statisti-
cally strong in 1997, one year after approval of the first currently used ChI. The first
signal was reported in an epidemiological study in 2009. For memantine, 69 sus-
pected cases were identified with the composite event. A statistically strong signal
of disproportionate reporting, adjusted for age, sex and year, was observed (EBGM
of 1.87; 90%CI: 1.47 – 2-38). Cumulative yearly analyses revealed that the signal
became statistically strong and stable two years after the first reported composite
event. No epidemiological studies have yet been published. CONCLUSIONS: Anal-
ysis of suspected events can be followed over time and may detect, confirm or
refute drug-event signals much earlier than epidemiological studies and inform
health technology assessments.
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OBJECTIVES: The impact on mortality is a major driver in determining the cost-
effectiveness of diagnostics and treatment of dementia disorders. We examined
the relationship between the degree of dementia severity and mortality in a longi-
tudinal, population-based study in Sweden.METHODS: From a total sample of 1810
subjects aged 75 years or older, 211 were identified as having a clinical diagnosis of
dementia at baseline and were included in the study. Disease severity was assessed
with the Mini-Mental State Examination (MMSE) as well as the Clinical Dementia
Rating (CDR), administered at baseline and again at two follow-up visits after ap-
proximately 40 and 80 months respectively. Mortality data was obtained from the
national death statistics, 10 years post baseline. Survival analysis was conducted
using Weibull regression with baseline as well as time-varying covariates. Age and
gender were also included as covariates in addition to dementia severity. RESULTS:
A total of 198 deaths were observed during the observation period, and the time to
death was 935 days on median. Annual mortality rates in females were estimated
to 12% for mild dementia (MMSE 21-26), 15% for moderate dementia (MMSE 10-20)
and 19% for severe dementia (MMSE 0-9) at baseline. The corresponding estimates
for males were 19%, 24% and 31% respectively. Each point lower result on the MMSE
scale was associated with a decrease in survival by 2.5%. There was no statistically
significant relationship between baseline CDR scores and mortality, though a trend
was seen towards increasing mortality in more severe CDR states. Similar results
were observed in an analysis incorporating changes in disease severity over time.
CONCLUSIONS: Mortality in subjects with dementia increase with the severity of
dementia, as measured by the MMSE. Incorporating differential survival by disease
severity has important implications for the long-term cost-effectiveness of diag-
nosis and therapies for dementia disorders.
Mental Health – Cost Studies
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OBJECTIVES: Prior to the approval of buprenorphine/naloxone (B/N) (Suboxone®)
we evaluated its economic impact in the treatment of heroin dependence. Three
years since its approval we aimed to reassess the economic impact of B/N consid-
ering the availability of data on its actual use in clinical practice and the changing
costs of medicines in the current economic crisis. A pharmacoeconomic modeling
was applied to evaluate the economic impact of B/N as a maintenance therapy for
opioid dependent individuals in the Spanish National Health Care System (NHS)
during a three-year period. METHODS: We used an interactive budgetary impact
analysis model that was developed to calculate the annual costs (drugs and asso-
ciated costs) to the Spanish NHS of methadone versus B/N depending on the num-
ber of patients receiving either medication. Data for the model were obtained from
scientific databases and expert panel opinion. RESULTS: It was estimated that
81.706 patients would be in agonist opioid maintenance treatment program each of
the three-years of the study. More importantly, the introduction of B/N combina-
tion has not resulted in an increase in the number of patients receiving treatment
for their opioid dependence. The budgetary impact (drugs and associated costs) for
opioid maintenance treatment in the first year of the study is expected to be 90,92
million €. In the first year of the pharmacoeconomic modeling the budgetary im-
pact of B/N would rise to 4.85 million € (4.9% of the total impact) to the NHS, with an
incremental cost of 0.86 million € (1.0% of the total impact). The mean cost per
patient in the first year with and without B/N has been calculated at € 1102 and
1113, respectively. CONCLUSIONS: With an additional cost of only € 11 per patient,
B/N is an efficient addition to the available pharmacotherapies for opioid depen-
dent patients, particularly when considering the favorable clinical aspects of this
novel medication.
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OBJECTIVES: To estimate the economic consequences of replacing the normal
tablets of quetiapine with Seroquel XR® in the treatment of schizophrenia in
Poland.METHODS: Based on the established model of the economic consequences
of schizophrenia treatment, we calculated the cost of treating schizophrenia with
quetiapine in Poland. Expenditures for the purchase of medicines, hospital costs
and the costs of lost productivity were highlighted. The analysis was performed
from a societal perspective, taking into account the Payer’s perspective, in one-year
time horizon. RESULTS: The use of Seroquel XR® will increase the population of
patients who comply with the recommended treatment, which will reduce the
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